Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acasti Pharma Inc (ACST.VN)

Acasti Pharma Inc (ACST.VN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 55,930
  • Shares Outstanding, K 90,209
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta -0.96
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.87
  • Most Recent Earnings -0.18 on 12/31/19
  • Next Earnings Date 02/14/20
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.10
  • Number of Estimates 4
  • High Estimate -0.03
  • Low Estimate -0.16
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +54.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.600 +3.33%
on 02/26/20
1.150 -46.09%
on 02/04/20
-0.250 (-28.74%)
since 01/24/20
3-Month
0.600 +3.33%
on 02/26/20
4.050 -84.69%
on 12/23/19
-1.990 (-76.25%)
since 11/26/19
52-Week
0.600 +3.33%
on 02/26/20
4.050 -84.69%
on 12/23/19
-0.780 (-55.71%)
since 02/26/19

Most Recent Stories

More News
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre...

ACST : 0.47 (-5.33%)
ACST.VN : 0.620 (-6.06%)
Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.47 (-5.33%)
ACST.VN : 0.620 (-6.06%)
Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre

Investigation underway into unexpected and inconsistent findings that may have negatively impacted results reported in TRILOGY 1

ACST : 0.47 (-5.33%)
ACST.VN : 0.620 (-6.06%)
Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduction in triglyceride levels among...

ACST : 0.47 (-5.33%)
ACST.VN : 0.620 (-6.06%)
IIROC Trading Resumption - ACST

Trading resumes in:

ACST : 0.47 (-5.33%)
ACST.VN : 0.620 (-6.06%)
IIROC Trading Resumption - ACST

VANCOUVER , Dec. 24, 2019 /CNW/ - Trading resumes in:

ACST.VN : 0.620 (-6.06%)
Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

Expects to report Trilogy 1 topline results in January 2020

ACST : 0.47 (-5.33%)
ACST.VN : 0.620 (-6.06%)
IIROC Trading Halt - ACST

The following issues have been halted by IIROC:

ACST : 0.47 (-5.33%)
ACST.VN : 0.620 (-6.06%)
IIROC Trading Halt - ACST

VANCOUVER , Dec. 23, 2019 /CNW/ - The following issues have been halted by IIROC:

ACST.VN : 0.620 (-6.06%)
Why the U.S. Remains the Largest Market for Medical Devices

Back in the end of 2018, a report from Moody's said that 2019 should be a standout year for the medical device industry. They added that revenue growth for device companies would be driven through innovation...

SOLY : 11.36 (-4.22%)
ATEC : 6.10 (-1.93%)
MDT : 106.15 (-2.19%)
IMGN : 4.64 (-2.93%)
ACST : 0.47 (-5.33%)
ACST.VN : 0.620 (-6.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Key Turning Points

2nd Resistance Point 0.687
1st Resistance Point 0.653
Last Price 0.620
1st Support Level 0.593
2nd Support Level 0.567

See More

52-Week High 4.050
Fibonacci 61.8% 2.732
Fibonacci 50% 2.325
Fibonacci 38.2% 1.918
Last Price 0.620
52-Week Low 0.600

See More

Business Summary

Acasti Pharma Inc is a biopharmaceutical company operating in Canada. It focuses on the research, development, and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. The key product candidate of the company, CaPre is developed for the treatment of severe hypertriglyceridemia,...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar